Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy

Document first published:
Page updated:
Publication type:
This document describes the evidence that has been considered by NHS England informulating a policy to routinely commission tolvaptan for hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy.